Skip to main content

Autoinflammatory

Has JAK POT Hit the Spot About Infection Risk? Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria. https://t.co/vN2VZYGqbE https://t.co/MQ3QCJU4SW
Dr. John Cush @RheumNow( View Tweet )
Does Withdrawing Steroids Increase Flares in SLE? Dr. Janet Pope reports on abstract OP0180 presented at Eular 2024 in Vienna, Austria. https://t.co/FjS0MBeWkv https://t.co/jeoO0gzz0K
Dr. John Cush @RheumNow( View Tweet )
DMARDs and Herpes Zoster Vaccination: To Stop or Not To Stop Dr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria. https://t.co/gKJRygBeq0 https://t.co/2NTNYJLPNZ
Dr. John Cush @RheumNow( View Tweet )
Difficult-to-treat Rheumatoid Arthritis: Validation of the EULAR Definition Dr. Mrinalini Dey discusses abstract OP0156 presented at Eular 2024 in Vienna, Austria. https://t.co/oc3Aj60KsM https://t.co/40FMjbKEHF
Dr. John Cush @RheumNow( View Tweet )
Giant Cell Arteritis and Polymyalgia Rheumatica Update Dr. Janet Pope discusses abstracts LBA0001, OP0233, OP0261 and POS0280 at Eular 2024 in Vienna, Austria. https://t.co/0V9Sle0GMU https://t.co/ixeT8L562C
Dr. John Cush @RheumNow( View Tweet )
Treat to Target Outcomes in Early AxSpA Dr. Antoni Chan discusses abstract OP0132 presented at Eular 2024 in Vienna, Austria. https://t.co/1svlH2GW9W https://t.co/oT1ZOPdR8e
Dr. John Cush @RheumNow( View Tweet )
A Step Closer to Identifying Phenotypes of RA ILD Dr. Mrinalini Dey discusses abstract OP0202 presented at Eular 2024 in Vienna, Austria. https://t.co/VUfsi3HnAA https://t.co/RA9kuuJSUS
Dr. John Cush @RheumNow( View Tweet )
When patients say their joints are swollen, what does it mean? Easy to dismiss it as a symptom, but this clinically suspect arthralgia cohort from Leiden shows: - some correlation w/ MRI/USS findings - predicts RA development - still worthwhile! #EULAR2024 POS0609 @drdavidliew https://t.co/cRl5ow1emE
Dr. John Cush @RheumNow( View Tweet )
Another proof (if needed) that controlling Dz Activity in RA is a very important preventive measure in RA! 179 pts ILD newly developed 9.5% progressed 12.3% no change 74.9% improved 4.5% 5.7% in the LDA group 28.0% non-LDA group (p=0.006) #EULAR2024 POS0408 @AurelieRheumo https://t.co/lKUY32KFiX
Dr. John Cush @RheumNow( View Tweet )
Does Telemonitoring in SpA Work? Dr. Antoni Chan reports on abstract OP0120 from Eular 2024 in Vienna, Austria. https://t.co/UUmnsAdx0t https://t.co/NE36OtKBwK
Dr. John Cush @RheumNow( View Tweet )
Do MRI changes at the Spine and SI Joints in Treatment of AxSpA Matter? Dr. Eric Ruderman discusses abstracts OP0046 and POS0058 presented at Eular 2024 in Vienna, Austria. https://t.co/hYy7Wg2GMJ https://t.co/GVjtf89c3t
Dr. John Cush @RheumNow( View Tweet )
RCT of #upadacitinib in #GCA It works to steroid spare 15 mg > 7.5 mg in outcomes Both >>placebo Ethically PBO had slower #prednisone taper Similar to #TCZ data What to choose in GCA IL6i? IL17i? JAKi? @eular_org # LBA0001 @Janetbirdope https://t.co/DGOltriVYF
Dr. John Cush @RheumNow( View Tweet )
Different pathways of auto inflammatory disease which is an amplifier system. Always check the phenotype first before genotype. Kasner D #EULAR2024 @RheumNow https://t.co/MtPzsVBNjn
Dr. Antoni Chan @synovialjoints( View Tweet )
NEW biomarkers in #MAS 1️⃣ IL-18 (available at some 🏥)⭐️ 2️⃣ S100A12 3️⃣ CXCL9/10 🚨When suspecting #MAS, don’t ignore the possibility of a monogenic disorder! 🎙️ Dr. Sophie Georgin-Lavialle 🇫🇷 #macrophage #EULAR2024 #genetics #rheumx https://t.co/Uot3JjrWs8
Artem Minalyan, MD, DABOM @AMinalyan( View Tweet )
Potential efficacy of JAK inhibitors in VEXAS syndrome #EULAR2024 NZ https://t.co/HziLUgo1gA
Annals of the Rheumatic Diseases @ARD_BMJ( View Tweet )
#Behcet’s #syndrome is increasing in the UK ? ⬆️ Detection ? Changing population demographics ? Other reasons Poster discussion POS0258 #EULAR2024 @RheumNow @eular_org @Pr1yankaC https://t.co/SEzmJnFMhM
Janet Pope @Janetbirdope( View Tweet )
Loved the talk on #VEXAS by @maferradastrong today at #EULAR2024 ! Amazing pictures to explain cellular level pathophysiology! Look for abnormal signs that arent otherwise explained to try to get to the diagnosis. @rheumnow https://t.co/YZmAqmFHpE
Bella Mehta @bella_mehta( View Tweet )
FDA has approved upadacitinib (Rinvoq), for use in pediatric patients (age >2 years) w/ active polyarticular juvenile idiopathic arthritis (pJIA) & psoriatic arthritis (PsA), after inadequate resp/intolerance to TNFi. Also available as oral solution. https://t.co/dZ21V2cKwR https://t.co/QADVP2w3Tz
Dr. John Cush @RheumNow( View Tweet )
2 large 48-wk phase 3 trials (Be HEARD I/II) of Bimekizumab vs PBO in moderate-to-severe hidradenitis suppurativa shows BKZ to be safe & significantly effective (48% vs 29% & 52% vs 32%) vs PBO. https://t.co/qJykCPMn4U https://t.co/zVOTxLkW9R https://t.co/3I4eOfPYWk
Dr. John Cush @RheumNow( View Tweet )
No Great Options for Treating VEXAS For patients w/ VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed. https://t.co/xCQYHwgUH9 https://t.co/N5Q03izr8u https://t.co/csIixQO3sJ
Dr. John Cush @RheumNow( View Tweet )

No Great Options for Treating VEXAS

MedPage Today

For patients with the auto-inflammatory disease VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed.

Among 110 patients in the

Read Article
Study of 187 Oligoarticular JIA pts - Remission was achieved w/ DMARDs in 65.8%; predictors of nonresponse (DMARD resistance) - Elevated CRP (> 1.1 mg/dL' OR 1.3) & and high JADAS-71 at Dx (> 15.8; OR 1.7) https://t.co/oPajnplXUL https://t.co/TnrknASCzb
Dr. John Cush @RheumNow( View Tweet )
Cutoffs for sJADAS10 An international cohort of children with systemic Juvenile idiopathic arthritis (Still's disease) validated the sJADAS10, a disease activity measure distinguish patients with ID, MiDA, MoDA, HDA. https://t.co/A0kIqiOWFE https://t.co/zShqs781W1
Dr. John Cush @RheumNow( View Tweet )